Skip to main content
OpenTrials
Completed

NCT Number: NCT04421885

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

A bioequivalence and food-effect study comparing two tablet formulations of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) in healthy adult subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Medical Facility

Tempe, Arizona, 85283, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, adult, male or female, 18 to 55 years of age
  • Continuous non-smoker.
  • Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs.
  • Has suitable venous access for repeated blood sampling.
  • A female of childbearing potential must agree to abstain from sexual activity that could lead to pregnancy.
  • A female of non-childbearing potential.
  • Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected to have during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease.
  • History of any illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  • History of significant allergic disease requiring treatment.
  • History or presence of alcoholism or drug abuse.
  • History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
  • History of known genetic metabolism anomaly associated with carnitine deficiency.
  • Female subjects with a positive pregnancy test or who are lactating.
  • Positive urine drug or alcohol results.
  • Positive results for human immunodeficiency virus (HIV 1 and 2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
  • QTcF interval is > 460 msec (males) or > 470 msec (females) or has ECG findings deemed abnormal with clinical significance by the PI or designee at the screening visit.
  • Estimated creatinine clearance < 80 mL/min at the screening visit.
  • Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements.

Treatment and study plan

Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference

Drug

600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.

Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test

Drug

600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.

Primary outcomes

  1. Area under the curve extrapolated to infinity (AUC0-∞).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  2. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  3. Maximum plasma concentration (Cmax).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

Secondary outcomes

  1. Time to the maximum plasma concentration (Tmax).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  2. Terminal elimination half-life (t½).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  3. Apparent total body clearance (CL/F)

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  4. Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  5. Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug.

    Time frame: 12 to 14 days after the last dose of study drug

    ECG, Clinical Laboratories, Vitals Signs and Physical Exams will be used as a safety measure to detect any AEs.

  6. Area under the curve extrapolated to infinity (AUC0-∞).

    Time frame: 24h (Day 2) post dose (Arms: B, C)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

  7. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t).

    Time frame: 24h (Day 2) post dose (Arms: B, C)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

  8. Maximum plasma concentration (Cmax).

    Time frame: 24h (Day 2) post dose (Arms: B, C)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

  9. Time to the maximum plasma concentration (Tmax).

    Time frame: 24h (Day 2) post dose (Arms: B, C)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

  10. Terminal elimination half-life (t½).

    Time frame: 24h (Day 2) post dose (Arms: B, C)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

  11. Apparent total body clearance (CL/F)

    Time frame: 24h (Day 2) post dose (Arms: B, C)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

  12. Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).

    Time frame: 24h (Day 2) post dose (Arms: B, C)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

Sponsors and collaborators

Lead sponsor

Spero Therapeutics

Industry

Registry information

Official study title

An Open-Label, Randomized, Single-Dose, Semi-Replicate, 4-Period, Crossover, Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jun 9, 2020
Registry last updated
Aug 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.